Sells it“Vraylar is indicated for acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar disorder in adults, acute treatment of depressive episodes associated with bipolar I disorder in adults and as an adjunctive treatment in major depressive disorder.”
Latest 10-KFY2025PositiveImpairment / charge ·
Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.
Revenue$61.2BYoY +8.6%
Net income$4.2BYoY −1.2%
Latest 10-QQ3 FY2026Positive ·
Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.
Revenue$17.4BYoY +10.3%
Net income$4.2Bvs $186.0M year ago
Latest 8-KLeadership change ·
Jennifer L. Davis resigned from AbbVie’s board following her appointment as Align Technology CEO.
Sells it“Carelon Services benefited from expansion in risk-based specialty and behavioral health and stronger specialty/home-based care performance, partly offset by the unaffiliated contract change and less favorable behavioral-health contract results.”
Latest 10-QQ3 FY2026Mixed ·
Carelon’s specialty pharmacy and care-services gains fell short of offsetting medical-cost pressure in Health Benefits.
Revenue$51.4BYoY +1.4%
Net income$1.4BYoY +14.8%
Latest 8-KGuidance reaffirmed ·
FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.
Latest 8-KPositiveEarningsGuidance raised ·
Carelon growth contrasts with Health Benefits weakness; FY2026 adjusted EPS outlook raised to ≥$29
Sells it 17%, $144.1M a year“Leveraging pharmacogenomics to help clinicians understand how genetics may impact patient metabolism and response to antidepressants and other mental health medications.”